The epidermis as a target for antipsoriatic treatment

REFERENCES

• Bos J D, van de Kerkhof P CM. Pathogenic aspects of psoriasis. Clin Dermatol 1995; 13: 97–190
   Google Scholar
• van de Kerkhof P CM, van Rennes H, de Good R, et al. Metabolic changes in the margin of the spreading psoriatic lesion. Br J Dermatol 1983; 108: 647–52
   Google Scholar
• De Jong E MGJ, Schalkwijk J, van de Kerkhof P CM. Epidermal proliferation and differentiation, composition of the inflammatory infiltrate and the extracellular matrix in the margin of the spreading psoriatic lesion. Eur J Dermatol 1991; 1: 221–7
   Google Scholar
• de Mare S, de Jong EJ MG, van Erp P EJ, et al. Markers for proliferation and keratinization in the margin of the active psoriatic plaque. Br J Dermatol 1990; 122: 469–75
   Google Scholar
• Gerritsen M JP, Elbers M E, de Jong E MGJ, et al. Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque. J Dermatol Sci 1997; 14: 179–88
   PubMedGoogle Scholar
• Leung D YM, Travers J B, Norris D A. the role of superantigens in skin disease. J Invest Dermatol 1995; 105: 37S–42S
   Google Scholar
• Nörholm-Pederson A. Infections and psoriasis. Acta Derm Venereol 1952; 32: 159–67
   Google Scholar
• Boehnke W H, Dressel D, Zollner T M, et al. Pulling the trigger on psoriasis. Nature 1996; 379: 777
   Google Scholar
• Norrlind R. The significance of infections in the origination of psoriasis. Acta Rheumatol Scand 1954; 1: 135–44
   Google Scholar
• Duvic M, Johnson T, Rapini R, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol 1987; 123: 1622–32
   PubMed Web of Science ®Google Scholar
• Bos J D, Meinardi M MH, vanJoost Th M, et al. Use of cyclosporin in psoriasis. Lancet 1989; 23/30: 1500–2
   Google Scholar
• Laburte C R, Grossman J, Abi-Rached J. Efficacy and safety of oral cyclosporin A for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366–75
   PubMed Web of Science ®Google Scholar
• Bos J D, Ruzicka Th, Rubins A, et al. European multicenter, randomized, double blind study to evaluate the safety and efficacy of FK506 (Tacrolimus) in the treatment of severe, recalcitrant plaque-type psoriasis. Skin Pharmacol 1995; 8: 74
   Google Scholar
• Gottlieb S L, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune, but not keratinocyte pathogenetic basis. Nat Med 1995; 1: 442–7
   PubMed Web of Science ®Google Scholar
• Rizova H. The effect of anti-CD4 monoclonal antibody treatment on immunological changes in psoriatic skin. J Dermatol Sci 1994; 7: 1–13
   PubMedGoogle Scholar
• Bata Csorgo Z, Hammerberg C, Voorhees J J, et al. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995; 95: 317–27
   Google Scholar
• Horn F, Marks F, Fisher G, et al. Decreased protein kinease C activity in psoriatic versus normal epidermis. J Invest Dermatol 1987; 88: 220–2
   Google Scholar
• Lowe N J, Breeding J, Ruissel D H. Cutaneous polyamine in psoriasis. Br J Dermatol 1982; 107: 21–6
   PubMed Web of Science ®Google Scholar
• Ziboh V A, Tamara L, Casebolt B S, et al. Biosynthesis of lipoxygenase products by enzyme preparations from normal and psoriatic skin. J Invest Dermatol 1984; 83: 426–30
   PubMedGoogle Scholar
• Forster S, Ilderton E, Summerly R, et al. The level of phospholipase A2 activity is raised in the uninvolved epidermis of psoriasis. Br J Dermatol 1983; 108: 103–8
   PubMed Web of Science ®Google Scholar
• Verhagen A, Bergers M, van Erp P EJ, et al. Confirmation of raised phospholipase A2 activity in the uninvolved skin of psoriasis. Br J Dermatol 1984; 110: 731–2
   Google Scholar
• van de Kerkhof P CM, van Erp P EJ. Calmodulin levels are grossly elevated in the psoriatic lesion. Br J Dermatol 1983; 108: 217–18
   Google Scholar
• Tucker W FG, MacNeil S, Bleehan S S, et al. Biologically active calmodulin levels are elevated in both involved and uninvolved epidermis in psoriasis. J Invest Dermatol 1984; 82: 298–9
   PubMed Web of Science ®Google Scholar
• Priestly G G. The fibroblast in psoriasis: master or slave?. Eur J Dermatol 1991; 1: 185–91
   Google Scholar
• Braverman I M, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982; 78: 12–17
   PubMed Web of Science ®Google Scholar
• Heng M CY, Allen S G, Chase D G. High endothelial venules in involved and uninvolved psoriatic skin: recognition by homing receptors on cytotoxic T lymphocytes. Br J Dermatol 1988; 118: 315–26
   PubMedGoogle Scholar
• Gerritsen M JP, van Vlijmen-Willems I MJJ, Chang A, et al. The effect of a hydrocolloid occlusive dressing (Duo-derm E) on keratinization in psoriasis vulgaris. Acta Derm Venereol (Stockh) 1994; 74: 483–4
   Google Scholar
• Gottlieb A B, Staiano Coico L, Cohen S R, et al. Occlusive hydrocolloid dressings decrease keratinocyte population growth fraction and clinical scale and skin thickness in active psoriatic plaques. J Dermatol Sci 1990; 1: 93–6
   PubMedGoogle Scholar
• Vonderheid E C, Bigler R D, Rogers T J, et al. Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. Yale J Biol Med 1989; 62: 653–64
   Google Scholar
• Melski W, Berkard J D, Stern R S. The Koebner (isomorphic) response in psoriasis. Arch Dermatol 1983; 119: 655–9
   PubMedGoogle Scholar
• Koebner H. Klinische, experimentelle und therapeutische Mitteilungen über Psoriasis. Berl Klin Wochenschr 1878; 21: 631–2
   Google Scholar
• Farber E M, Roth R J, Arschheim E, et al. Role of trauma in isomorphic response in psoriasis. Arch Dermatol 1965; 91: 246–51
   PubMedGoogle Scholar
• Pedace J, Muller A, Winkelmann R K. Biology of psoriasis; experimental study of Koebner phenomenon. Acta Derm Venereol (Stockh) 1969; 49: 390–400
   PubMedGoogle Scholar
• Eyre R W, Krueger G P. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner reactions. Br J Dermatol 1982; 106: 153–9
   PubMed Web of Science ®Google Scholar
• van de Kerkhof P CM. Methotrexate. Textbook of psoriasis, P D Mier, P CM van de Kerkhof. Churchill Livingstone, Edinburgh 1986; 233–51
   Google Scholar
• Schwartz P M, Barnett S K, Atillasoy E S, et al. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci USA 1992; 89: 594–8
   Google Scholar
• Furue M, Gaspari A A, Katz S L. The effect of cyclosporin A on epidermal cells. II. Cyclosporin A inhibits proliferation of normal and transformed keratinocytes. J Invest Dermatol 1988; 90: 796–800
   Google Scholar
• Steiner J P, Dawson T M, Fotuhi M, et al. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 1992; 358: 584–7
   PubMed Web of Science ®Google Scholar
• Fisher G J, Duell E A, Nickoloff B J, et al. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol 1988; 91: 142–6
   PubMed Web of Science ®Google Scholar
• Khandke L, Krane J F, Ashinoff R, et al. Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. Arch Dermatol 1991; 127: 1172–9
   Google Scholar
• Dykes P J, Brunt J, Marks R. The effect of cyclosporin on human epidermal keratinocytes in vitro. Br J Dermatol 1990; 122: 173–80
   Google Scholar
• Pilkington T, Brogden R N. Acitretin. A review of its pharmacology and therapeutic use. Drugs 1992; 43: 597–627
   PubMed Web of Science ®Google Scholar
• Carlberg C, Bendik I, Wyss A. Two nuclear signalling pathways for vitamin D. Nature 1993; 361: 657–60
   PubMed Web of Science ®Google Scholar
• Raynaud F, Gerbaud P, Bouloc A, et al. Rapid effect of treatment of psoriatic erythrocytes with the synthetic retinoid acitretin to increase 8-azido cyclin AMP binding to the RI regulatory subunit. J Invest Dermatol 1993; 100: 77–81
   Google Scholar
• Finzi E, Blake M J, Celano P, et al. Cellular localization of retinoic acid receptor-gamma expression in normal and neoplastic skin. Am J Pathol 1992; 140: 1463–71
   PubMed Web of Science ®Google Scholar
• Elder J T, Astrom A, Pettersson U, et al. Retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 1992; 98: 36S–41S
   PubMed Web of Science ®Google Scholar
• Eichner R, Kahn M, Capetola J. Effects of topical retinoids on cytoskeletal proteins: implications for retinoid effects on epidermal differentiation. J Invest Dermatol 1992; 98: 154–61
   PubMed Web of Science ®Google Scholar
• Stellmach V, Leask A, Fuchs E. Retinoid-mediated transcriptional regulation of keratin genes in human epidermal and squamous cell carcinoma cells. Proc Natl Acad Sci USA 1991; 88: 4582–6
   PubMed Web of Science ®Google Scholar
• West M R, Page J M, Turner D M, et al. Simple assays of retinoid activity as potential screens for compounds that may be useful in treatment of psoriasis. J Invest Dermatol 1992; 99: 95–100
   Google Scholar
• Michel S, Courseaux A, Miquel C, et al. Determination of retinoid activity by an enzyme-linked immunosorbent assay. Anal Biochem 1991; 192: 232–6
   Google Scholar
• Hickok N J, Uitto J. Regulation of ornithine decarboxylase gene expression, polyamine levels, and DNA synthetic rates by all-trans-retinoic acid in cultured human keratinocytes. J Invest Dermatol 1992; 98: 327–32
   Google Scholar
• Olsen D R, Hickok N J, Uitto J. Suppression of ornithine decarboxylase gene expression by retinoids in cultured human keratinocytes. J Invest Dermatol 1990; 94: 33–6
   Google Scholar
• Varani J, Nickoloff B J, Dixit V M, et al. All-trans-retinoic acid stimulates growth of adult human keratinocytes cultured in growth factor-deficient medium, inhibits production of thrombospondin and fibronectin, and reduces adhesion. J Invest Dermatol 1989; 93: 449–54
   PubMed Web of Science ®Google Scholar
• Tong P S, Horowitz N N, Wheeler L A. Trans-retinoic acid enhances the growth response of epidermal keratinocytes to epidermal growth factor and transforming growth factor beta. J Invest Dermatol 1990; 94: 126–31
   PubMed Web of Science ®Google Scholar
• Pathak M A. Mechanisms of psoralen photosensitization reactions. Natl Cancer Inst Monogr 1984; 66: 41–66
   PubMedGoogle Scholar
• Bertaux B, Moreno G, Vinzens F, et al. Autoradiographic study of the effects of psoralen and ultraviolet light on DNA, RNA and protein synthesis in cultured keratinocytes and psoriatic skin. Skin Pharmacol 1988; 1: 250–8
   Google Scholar
• Luger T A, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol 1990; 95: 100S–104S
   PubMed Web of Science ®Google Scholar
• Simon M M, Aragane Y, Schwarz A, et al. UVB light induces nuclear factor kappaB (NFkB) activity independently from chromosomal DNA damage in cell-free cytosolic extracts. J Invest Dermatol 1994; 102: 422–7
   PubMedGoogle Scholar
• Fuchs J, Nitschmann W H, Packer L. The antipsoriatic compound anthralin influences bioenergetic parameters and redox properties of energy transducing membranes. J Invest Dermatol 1990; 94: 71–6
   PubMedGoogle Scholar
• Gottlieb A B, Khandke L, Krane J F, et al. Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro. J Invest Dermatol 1992; 98: 680–5
   PubMed Web of Science ®Google Scholar
• Müller M, Renkawitz R. The glucocorticoid receptor. Biochim Biophys Acta 1991; 1088: 171–82
   PubMed Web of Science ®Google Scholar
• Caldenhoven E, Liden J, Wissink S, et al. Negative crosstalk between Rel A and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995; 9: 401–12
   PubMedGoogle Scholar
• Marcelo C L, Tomich J, Cyclic A MP. glucocorticoid, and retinoid modulation of in vitro keratinocyte growth. J Invest Dermatol 1983; 81: 64S–68S
   Google Scholar
• Binderup L, Kragballe K. Origin of the use of calcipotriol in psoriasis treatment. Rev Contemp Pharmacother 1992; 3: 357–65
   Google Scholar
• van de Kerkhof P CM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995; 132: 675–82
   PubMed Web of Science ®Google Scholar
• Tomic M, Jiang C K, Connolly D, et al. Vitamin D3, its receptor and regulation of epidermal keratin gene expression. Epithelial Cell Biol 1992; 1: 70–5
   PubMedGoogle Scholar
• Bittiner B, Bleehen S S, MacNeil S. 1 Alpha, 25(OH)2 vitamin D3 increases intracellular calcium in human keratinocytes. Br J Dermatol 1991; 124: 230–5
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Hashimoto K, Nishida Y, et al. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 1990; 166: 916–23
   PubMed Web of Science ®Google Scholar
• Kitano Y, Ikeda N, Okano M. Suppression of proliferation of human epidermal keratinocytes by 1,25-dihydroxyvitamin D3. Eur J Clin Invest 1991; 21: 53–8
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Yamamoto M, Mimura H, et al. 1,24(R)-Dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J Dermatol 1990; 17: 135–42
   PubMedGoogle Scholar
• Kobayashi T, Okumura H, Azuma Y, et al. 1 alpha, 24R-dihydroxyvitamin D3 to induce keratinocyte differentiation. J Dermatol 1990; 17: 707–9
   PubMedGoogle Scholar
• Bikle D D, Gee E, Pillai S. Regulation of keratinocyte growth, differentiation and vitamin D metabolism by analogues of 1,25-dihydroxyvitamin D. J Invest Dermatol 1993; 101: 713–18
   PubMed Web of Science ®Google Scholar
• Biro L, Carriere R, Lawrence F, et al. Morphological changes induced by methotrexate. J Invest Dermatol 1967; 48: 429–37
   Google Scholar
• Ellis Ch N, Gorsulowski D C, Hamilton T A, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110–16
   PubMed Web of Science ®Google Scholar
• de Jong E MGJ. Dynamics of epidermal growth and inflammation in psoriasis. Thesis, Nijmegen. 1993
   Google Scholar
• de Jong E MGJ, van de Kerkhof P CM. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long term treatment with the vitamin D3 analogue MC 903; modulations and interrelations. Br J Dermatol 1991; 124: 221–9
   PubMed Web of Science ®Google Scholar
• de Jong E MGJ, Ferrier C M, de Zwart A J, et al. Effect of topical treatment with Budesonide (Preferid) on clinical scores and on parameters for proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9: 185–94
   PubMedGoogle Scholar
• de Jong E MGJ, van de Kerkhof P CM. Short contact dithranol treatment of psoriasis, using a novel emulsifying ointment (Hermal AW). Eur J Dermatol 1992; 2: 552–8
   Google Scholar
• Gerritsen M JP, Rulo H FC, van Vlijmen-Willems J, et al. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study. Br J Dermatol 1993; 128: 666–73
   PubMedGoogle Scholar
• Gerritsen M JP, Boezeman J BM, van Vlijmen-Willems I MJJ, et al. The effect of Tacalcitol (1,24 (OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis, a placebo-controlled, double-blind study. Br J Dermatol 1994; 131: 57–63
   PubMed Web of Science ®Google Scholar
• Gerritsen M JP, van Erp P EJ, van de Kerkhof P CM. Transglutaminase positive cells in psoriatic epidermis during treatment with calcitriol (1α,25 dihydroxy vitamin D3) and tacalcitol (1α,24 dihydroxy vitamin D3). Br J Dermatol 1995; 133: 653–66
   Google Scholar
• Gerritsen M JP, van Vlijmen-Willems I MJJ, Chang A, et al. The effect of a hydrocolloid occlusive dressing (Duo-DERM E) on keratinization in psoriasis vulgaris. Acta Derm Venereol (Stockh) 1994; 74: 483–4
   Google Scholar
• van der Vleuten C JM, de Jong E MGJ, van de Kerkhof P CM. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996; 288: 366–72
   PubMedGoogle Scholar
• van der Vleuten C JM, van Vlijmen-Willems I MJJ, de Jong E MGJ, et al. Clobetasol-17-propionate lotion under hydrocolloid dressing (Actiderm) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Br J Dermatol, (submitted).
   Google Scholar
• van der Vleuten C JM, de Jong E MGJ, van de Kerkhof P CM. Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream. Clin Exp Dermatol 1996, (in press).
   Google Scholar
• van der Vleuten C JM, Gerritsen M JP, de Jong E MGJ, et al. A novel dithranol formulation (Micanol): the effects of monotherapy of dithranol and UVB combination, proliferation and cutaneous inflammation in psoriasis. Acta Derm Venereol 1996; 76: 387–91
   Google Scholar
• Braun-Falco O, Schoefinius H H. Ueber die Wirkung von Dithranol (Cignolin) bei psoriasis vulgaris. Arch Dermatol Forsch 1971; 241: 217–36
   Google Scholar
• Wantzin G L, Thomsen K. Methotrexate in lymphomatoid papulosis. Br J Dermatol 1984; 111: 93–5
   Google Scholar
• Metzger A L, Bohan A, Goldberg L S. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182–9
   PubMed Web of Science ®Google Scholar
• Knowles W R, Chernosky M E. Pityriasis rubra pilaris. Prolonged treatment with methotrexate. Arch Dermatol 1970; 102: 603–12
   PubMedGoogle Scholar
• Happle R, van de Kerkhof P CM, Traupe H. Retinoids in disorders of keratinization: their use in adults. Dermatologica 1987; 175(S1): 107–24
   Google Scholar
• van de Kerkhof P CM, Chang A. Migration of polymorphonuclear leukocytes in psoriasis. Skin Pharmacol 1989; 2: 138–54
   Google Scholar
• Mahrle G, Thiele B. Retinoids in cutaneous T cell lymphoma. Dermatologica 1987; 175(S1): 145–50
   Google Scholar
• Kragballe K, Steijlen P M, van de Kerkhof P CM, et al. Efficacy tolerability and safety of calcipotriol ointment in disorders of keratinization. Arch Dermatol 1995; 131: 556–60
   PubMed Web of Science ®Google Scholar
• Ross J S, Camp R DR. Cyclosporin A in atopic dermatitis. Br J Dermatol 1990; 122(Suppl 36)41–5
   PubMedGoogle Scholar
• Berth-Jones J, Bourke J, Bailey K. Generalised pustular psoriasis: response to topical calcipotriol. B M J 1992; 305: 868–9
   PubMedGoogle Scholar
• Kuypers A, van Dooren-Greebe R J, van de Kerkhof P CM. Acrodermatitis continua Hallopeau response to combined treatment with acitretin and calcipotriol ointment. Dermatology 1996; 192: 357–9
   Google Scholar
• Grossman R M, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo controlled study. J Am Acad Dermatol 1994; 31: 68–74
   PubMed Web of Science ®Google Scholar
• van de Kerkhof P CM. Dithranol treatment for psoriasis. After 75 years, still going strong. Eur J Dermatol 1991; 1: 79–89
   Google Scholar
• Kerscher M, Plewig G, Lehmann P. Kombinationstherapie der Psoriasis vulgaris mit einem Schmalspectrum UVB-Strahler (Philips TL 01, 311 nm) und Calcipotriol. Aktuelle Dermatol 1994; 20: 151–4
   Google Scholar
• Frappaz A, Thivolet J. Calcipotriol in combination with PUVA; a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993; 3: 351–4
   Google Scholar
• Orfanos C E, Steigleder G K, Pullman H, et al. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an outpatient basis. Acta Derm Venereol (Stockh) 1979; 59: 241–4
   PubMed Web of Science ®Google Scholar
• Fritsch P O, Hönigsmann H, Jaschke E, et al. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoid derivative. J Invest dermatol 1978; 70: 178–82
   Web of Science ®Google Scholar